Summary

Eligibility
for males ages 18 years and up (full criteria)
Location
at UCLA
Dates
study started
study ends around
Principal Investigator
by Robert Reiter, M.D. (ucla)

Description

Summary

Prostate cancer is the most common cancer in men and the second leading cause of cancer death in men. The purpose of this research study is to compare prostate cancers treated with hormone therapy versus prostate cancers treated with hormone therapy plus drugs that directly target cancer cells.

Official Title

An Open-label, Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With and Without SRC or MEK Inhibition on the Development of EMT in Prostate Cancer

Details

Most prostate cancers respond to hormone therapy, also known as chemical castration. Unfortunately, castration resistance may occur in certain prostate cancers. Castration resistance or hormone refractory prostate cancer means that the cancer continues to progress as seen by progressively rising PSA and/or or an increase in tumor mass on bone scan, X-ray, CT scan or MRI despite previous hormonal therapy. The researchers are interested in understanding mechanisms of castration resistance in prostate cancer by analyzing prostate tissue before radical prostatectomy (from prostate biopsy tissue) and after radical prostatectomy (whole prostate specimen). They will look at the "molecular signature" of prostate cancer cells after hormone therapy to identify the key steps that the cancer cells undergo to become resistant to hormone therapy. In addition, the researchers will use other medications in addition to hormone therapy in order to block some of the key biochemical steps that are thought to mediate treatment resistance. This research will provide crucial information for the development of therapies that can improve the clinical outcome of patients with advanced prostate cancer.

Keywords

Prostate Cancer, hormone therapy, radical prostatectomy, Prostatic Neoplasms, Dasatinib, Trametinib, degarelix, enzalutamide, AR inhibition plus MEK inhibition, AR inhibition plus SRC inhibition

Eligibility

Location

  • University of California, Los Angeles
    Los Angeles California 90095 United States

Lead Scientist at University of California Health

  • Robert Reiter, M.D. (ucla)
    Dr. Robert E. Reiter holds the Bing Professorship of Urologic Research.

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Jonsson Comprehensive Cancer Center
ID
NCT01990196
Phase
Phase 2 Prostate Cancer Research Study
Study Type
Interventional
Participants
About 45 people participating
Last Updated